​

Gossamer Bio (GOSS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Gossamer Bio Revenue Highlights

Latest Revenue (Y)

$114.70M

Latest Revenue (Q)

$9.89M

Main Segment (Y)

License and Service

Gossamer Bio Revenue by Period

Gossamer Bio Revenue by Year

DateRevenueChange
2024-12-31$114.70M100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

Gossamer Bio generated $114.70M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Gossamer Bio Revenue by Quarter

DateRevenueChange
2025-03-31$9.89M5.44%
2024-12-31$9.38M-1.07%
2024-09-30$9.48M-90.11%
2024-06-30$95.84M100.00%
2024-03-31--100.00%
2023-12-31$6.78M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--

Gossamer Bio generated $9.89M in revenue during Q1 2025, up 5.44% compared to the previous quarter, and up 145.77% compared to the same period a year ago.

Gossamer Bio Revenue Breakdown

Gossamer Bio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
License and Service$90.68M

Gossamer Bio's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24
License and Service-

Gossamer Bio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GOSSGossamer Bio$114.70M$9.89M
ALECAlector$100.56M$54.24M
AMLXAmylyx Pharmaceuticals$87.37M$-665.00K
STOKStoke Therapeutics$36.55M$22.61M
KRONKronos Bio$9.85M$2.27M
XFORX4 Pharmaceuticals$2.56M$28.81M
LYRALyra Therapeutics$1.53M$209.00K
AKROAkero Therapeutics--
BDTXBlack Diamond Therapeutics--
FDMT4D Molecular Therapeutics-$1.00K
REPLReplimune Group--
ABOSAcumen Pharmaceuticals--
NVCTNuvectis Pharma--
INZYInozyme Pharma--
TERNTerns Pharmaceuticals--
PASGPassage Bio--
BMEABiomea Fusion--

GOSS Revenue FAQ

What is Gossamer Bio’s yearly revenue?

Gossamer Bio's yearly revenue for 2024 was $114.7M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. GOSS's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Gossamer Bio’s quarterly revenue?

Gossamer Bio's quarterly revenue for Q1 2025 was $9.89M, a 5.44% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $9.38M, a -1.07% decrease from the previous quarter (Q3 2024), and a 38.25% increase year-over-year (Q4 2023). GOSS's quarterly revenue for Q3 2024 was $9.48M, a -90.11% decrease from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023).

What is Gossamer Bio’s revenue growth rate?

Gossamer Bio's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Gossamer Bio’s revenue streams?

Gossamer Bio's revenue streams in c 24 are License and Service

What is Gossamer Bio’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Gossamer Bio was License and Service. This segment made a revenue of $90.68M, representing 100.00% of the company's total revenue.